louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04081285: Epigenetic Biomarkers for Alzheimer's Disease
Official title: Identification of Epigenetic Biomarkers for Alzheimer's Disease in Blood Using Epigenome-wide Analysis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Alzheimer Disease
Lead sponsor: Chinese University of Hong Kong
Sponsor class: OTHER
Collaborators: name: Hong Kong University of Science and Technology
First posted: 2019-09-09
Enrollment: 250
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Alzheimer's disease patients and normal siblings

Brief summary: Alzheimer's disease (AD) is a neurodegenerative disorder with no know cure. The pathogenesis of late onset AD (LOAD) is complex and multifactorial in nature, with multiple susceptibility genes and environmental factors at interplay.

The objective of this study is to improve our understanding of the risk factors of LOAD by conducting an epigenome wide study within patients of LOAD contrasted against their cognitively normal siblings.


Eligibility criteria: Inclusion Criteria:

* Sufficient Cantonese competency for cognitive test
* Written informed consent given
* Have at least one gender-matched cognitively normal sibling

Exclusion Criteria:

* Subjects who refuse blood taking procedure
* Do not have a reliable family/caregiver informant (personal contact at least once a month)

Primary outcomes:
measure: DNA methylation
timeFrame: 5 years
measure: RNA-seq microbiome
timeFrame: 5 years
measure: Alzheimer's disease Assessment Scale-cognitive subscale (Adas-Cog)
timeFrame: 5 years
Secondary outcomes:
Other outcomes:
Locations:
city: Hong Kong
country: Hong Kong
facility: The Chinese University of Hong Kong
Study officials:
affiliation: Chinese University of Hong Kong
name: Timothy Kwok
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00874185: Satisfaction With Phosphodiesterase 5 Inhibitors Treatment In Patients With Cardiovascular Risk
Official title: Satisfaction With Treatment In Patients With Erectile Dysfunction And Cardiovascular Risk And/Or Previous Cardiovascular Event.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Erectile Dysfunction
Keywords: satisfaction
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2009-04-02
Enrollment: 720
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: People with cv risk

Brief summary: Evaluate satisfaction in people treated with IPDE5 inhibitors over time

Detailed description: 12 first patients that are eligible

Eligibility criteria: Inclusion Criteria:

* CV risk factors
* Male above 18

Exclusion Criteria:

* Non-informed consent

Primary outcomes:
measure: EDITS
timeFrame: 6 months
measure: SEAR
timeFrame: 6 months
Secondary outcomes:
measure: Medication prescribed
timeFrame: 6 months
Other outcomes:
Locations:
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References:
Clinical trial NCT06945185: Motor Imagery Training for Upper Limb Functional Strength in Chronic Stroke Patients
Official title: Motor Imagery Training for Upper Limb Functional Strength in Chronic Stroke Patients
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Chronic Stroke
Keywords: Motor Imagery
Stroke
Neurorehabilitation
Functional strength
Lead sponsor: Foundation University Islamabad
Sponsor class: OTHER
First posted: 2025-04-25
Enrollment: 26
Sex: ALL
Minimum age (years): 45
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Stroke is a leading cause of upper extremity deficits worldwide. Persistent upper extremity dysfunction affects many post stroke patients and is strongly associated with decreased activities of daily living and poor quality of life.

There is accumulating evidence of a cross-over effect with training of one limb that slightly increase strength and coordination in contralateral untrained limb through neurological adaptations.

One of rehabilitation that is beneficial for stroke patient is motor imagery, a mental rehearsal of a movement that does not include physical movement has been shown to enhance upper limb function.

Evidence demonstrate that MI not only activates motor cortical and subcortical regions but also induces plastic change in motor networks and modulates synaptic activity at spinal level.

Detailed description: OBJECTIVE:

The objectives of this study are:

1. To improve upper limb functional strength.
2. To improve the upper limb coordination.
3. To improve upper limb functional improvement.

HYPOTHESIS

Alternate Hypothesis:

There will be statistically significant difference in effects of motor imagery technique combined with conventional physical therapy and in comparison to conventional physical therapy alone on upper limb functional strength, coordination and functional improvement in chronic stroke. (p\<0.05).

Null Hypothesis:

There will be no statistically significant difference in effects of motor imagery technique combined with conventional physical therapy and in comparison to conventional physical therapy alone on upper limb functional strength, coordination and functional improvement in chronic stroke. (p\>0.05).

Research Design: Experimental study. Randomized Control Trial

Eligibility criteria: Inclusion Criteria:

* Stroke duration 6 months onwards (chronic stroke).
* age 45 years and above.
* Both genders.
* Access cognitive function score \> 24 on MoCA.

Exclusion Criteria:

* Patients with any comorbidity, previous surgery and congenital anomly.
* Patient with any fracture/ MSK disorders.
* Score 3 or more on Modified Ashworth scale.
* Patients with hearing impairments

Primary outcomes:
measure: FUNCTIONAL STRENGTH
timeFrame: 8 weeks
measure: Coordination
timeFrame: 8 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Islamabad
country: Pakistan
facility: Foundation University College of Physical Thrapy
Study officials:
References:
Clinical trial NCT01803815: Evaluation of Antihypertensive Drugs in OSA Patients
Official title: Evaluation of Antihypertensive Drugs in Patients With Obstructive Sleep Apnea
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hypertension
Obstructive Sleep Apnea
Keywords: obstructive sleep apnea
hypertension
antihypertensive drugs
Lead sponsor: Universidade Nova de Lisboa
Sponsor class: OTHER
First posted: 2013-03-04
Enrollment: 369
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Consecutive patients, male and women, aged above 18 years, that attended a first visit at CHLN Hospital Sleep Unit, located in Lisbon, were enrolled.

Brief summary: This prospective cohort study aimed to assess the phenotypic characteristics of OSA patients and their pattern of antihypertensive drugs consumption. The investigators also aimed to investigate a hypothetical association between ongoing anti-hypertensive regimen and Blood pressure control rates in these patients. Additionally, the investigators were also interested in trying to understand if the control of OSA may be influenced by the use of different classes of anti-hypertensive drugs.


Eligibility criteria: Inclusion Criteria:

* aged above 18 years, that attended a first visit at CHLN Hospital Sleep Unit were enrolled

Exclusion Criteria:

* severe psychiatric disease or inability to understand the information required for an informed consent.

Primary outcomes:
measure: Number of participants with uncontrolled BP before CPAP (Continuous Positive Airway Pressure) adaptation.
timeFrame: patients will be followed up for an expected average time of 2 months
Secondary outcomes:
Other outcomes:
Locations:
city: Lisboa
country: Portugal
facility: Universidade Nova de Lisboa - Faculdade de Ciências Médicas
Study officials:
affiliation: Universidade Nova de Lisboa - CEDOC
name: Lucilia N Diogo, PharmD, MSc
role: PRINCIPAL_INVESTIGATOR
affiliation: CHLN
name: Paula Pinto, PhD, MD
role: STUDY_CHAIR
affiliation: CHLN
name: Cristina Bárbara, PhD, MD
role: STUDY_CHAIR
affiliation: Universidade Nova de Lisboa
name: Emilia C Monteiro, PhD, MD
role: STUDY_DIRECTOR
affiliation: Universidade Nova de Lisboa
name: Ana L Papoila, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT01495715: Study With Idebenone in Patients With Chronic Vision Loss Due to Leber's Hereditary Optic Neuropathy (LHON)
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE3
Conditions: Leber's Hereditary Optic Neuropathy
Lead sponsor: Santhera Pharmaceuticals
Sponsor class: INDUSTRY
First posted: 2011-12-20
Enrollment: 0
Sex: ALL
Minimum age (years): 10
Maximum age (years): 65
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no

Brief summary: The objective of the study is to determine whether administration of idebenone can shorten the time to improvement of visual acuity in patients with chronic vision loss due to LHON.


Eligibility criteria: Inclusion Criteria:

* Age \> or equal 10 years and \< 65 years
* Impaired visual acuity in affected eyes due to LHON: Visual acuity in best eye \>0.4 logMAR
* No explanation for visual loss besides LHON

Exclusion Criteria:

* Any previous use of idebenone
* Participation in another clinical trial of any investigational drug within 3 months prior to Baseline
* Previous participation in Study SNT-II-003 (RHODOS) for idebenone.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03770715: Sleep Apnea After Extubation
Official title: Sleep Apnea After Extubation
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Sleep Apnea
Keywords: Sleep Apnea
Respiratory polygraphy
Extubation
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2018-12-10
Enrollment: 13
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Tertiary referral hospital

Brief summary: Sleep apnea is common after extubation, approximately 71%, and is independently associated with hypertension and metabolic disease contributing to increased morbidity and mortality. Respiratory polygraphy is a simpler alternative to in-laboratory polysomnography for the management of more symptomatic patients with obstructive sleep apnea.

The aim of this study is to evaluate the prevalence of sleep apnea after extubation by respiratory polygraphy.


Eligibility criteria: Inclusion Criteria:

* patients after extubation

Exclusion Criteria:

* pregnant
* non-consciousness
* received continuous positive airway pressure (CPAP)

Primary outcomes:
measure: Prevalence of sleep apnea after exutbation
timeFrame: during first to second night following extubation
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
Study officials:
affiliation: Seoul National University Hospital
name: Jaeyoung Cho, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03772015: The Change in Vaginal Axis on MRI After Uterus Preserving Laparoscopic Lateral Mesh Suspension
Official title: The Change in Vaginal Axis on MRI After Uterus Preserving Laparoscopic Lateral Mesh Suspension
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Prolapse Genital
Anatomical Pathological Condition
Keywords: laparoscopic lateral mesh suspension
lateral abdominocervicopexy
apical prolapse
anterior prolapse
vaginal axis
magnetic resonance imaging
Lead sponsor: Sisli Hamidiye Etfal Training and Research Hospital
Sponsor class: OTHER
Collaborators: name: Bartin State Hospital
First posted: 2018-12-11
Enrollment: 21
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients who are scheduled for lateral mesh suspension operation to treat apical prolapse.

Brief summary: Laparoscopic lateral mesh suspension is emerged as a practical, safe and feasible alternative to sacropexy to treat female genital apical prolapse. Investigators hypothesized that uterus-preserving lateral suspension provides a better anatomical positioning.

Detailed description: Suspending the cervix to the bilateral abdominal wall through subperitoneal tunnels may properly mimic cardinal ligament and restore the normal vaginal axis. To prove the null hypothesis, it is planned to compare the vaginal axis on Magnetic Resonans Imaging taken preoperatively and postoperatively in patients who are scheduled for lateral mesh suspension for apical prolapse.

Eligibility criteria: Inclusion Criteria:

* Female genital prolapse

Exclusion Criteria:

* Patients who had pouch of Douglas obliteration
* Patients with enterocele
* Patients who have any congenital or acquired anatomic and reproductive anomaly

Primary outcomes:
measure: Vaginal axis
timeFrame: at 6th months after the operation
measure: Vaginal distances
timeFrame: at 6th months after the operation
Secondary outcomes:
measure: Urge Symptoms
timeFrame: Evaluation at postoperative 6th month
measure: Prolapse symptoms
timeFrame: Evaluation at postoperative 6th month
measure: Sexual functions
timeFrame: Evaluation at postoperative 6th month
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Hamidiye Sisli Etfal Training and Research Hospital
Study officials:
affiliation: Hamidiye Sisli Etfal Training and Research Hospital
name: Ozan Dogan, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Bartin State Hospital
name: Murat Yassa, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Senturk MB, Kilicci C, Aydin S, Polat M, Abide Yayla C, Karateke A. Vaginal axis on MRI after unilateral and bilateral sacral hysteropexy: a controlled study. J Obstet Gynaecol. 2018 Jan;38(1):115-120. doi: 10.1080/01443615.2017.1336754. Epub 2017 Aug 17.
Clinical trial NCT05971615: Evaluate the Relevance of the Use of Peripheral Venous Blood Gases for the Care of Patients in the S.A.U.V (Vital Emergency Rooms) of the CHU de Caen
Official title: Evaluate the Relevance of the Use of Peripheral Venous Blood Gases for the Care of Patients in the S.A.U.V (Vital Emergency Rooms) of the CHU de Caen
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Critical Illness
Lead sponsor: University Hospital, Caen
Sponsor class: OTHER
First posted: 2023-08-02
Enrollment: 90
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: concordance between the lactate values on peripheral venous and arterial blood gases in all patients receiving an arterial sample on their arrival in the S.A.U.V.


Eligibility criteria: Inclusion Criteria:

* one of this condition in emergency unit :

  1. acute respiratory distress
  2. a suspicion of an acid-base disorder
  3. a state of shock
  4. Pathologies requiring monitoring of the respiratory system
  5. Patient under NIV
  6. Poisoning
  7. Coma with a Glasgow score \< or equal to 8

Exclusion Criteria:

* Patient presenting another pathology supported in SAUV not requiring the realization of arterial blood gases
* Patient aged \< 18 years
* Pregnant or breastfeeding woman

Primary outcomes:
measure: lactates on peripheral venous and arterial blood gases
timeFrame: baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Caen
country: France
facility: CAEN University Hospital
Study officials:
References:
Clinical trial NCT02102815: Efficacy of Preoperative Intravenous Dexamethasone in Primary Total Knee Arthroplasty
Official title: Efficacy of Preoperative Intravenous Dexamethasone in Controlling Postoperative Pain After Primary Total Knee Arthroplasty: A Randomized Double-blinded Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Postoperative Pain
Keywords: total knee arthroplasty
pain control
dexamethasone
steroids
Lead sponsor: Thammasat University
Sponsor class: OTHER
First posted: 2014-04-03
Enrollment: 100
Sex: ALL
Minimum age (years): 50
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To determine efficacy of preoperative IV dexamethasone for postoperative pain control after TKA.

Detailed description: Preoperative intravenous over 0.1 mg/kg of dexamethasone could be reduced pain after primary TKA.

Eligibility criteria: Inclusion Criteria:

* Osteoarthritis of the knee who undergoing unilateral primary total knee arthroplasty
* 50-85 years old
* ASA class 1-3

Exclusion Criteria:

* Unable to perform spinal anaesthesia
* History of drug allergies: steroids
* Renal impairment (CrCl \<30 mL/min)
* Liver impairment
* Cognitive function disorders
* Poor controlled DM (HA1C \> 7.5)
* Morning DTX at operative day \> 180 mg%
* Received corticosteroids within 3 months before surgery

Primary outcomes:
measure: post-operative pain
timeFrame: 48 hours
Secondary outcomes:
measure: Functional knee score
timeFrame: 3 month
measure: post-operative nausea and vomiting
timeFrame: 48 hours
measure: complication of preoperative dexamethasone
timeFrame: 2 weeks
measure: inflammatory level
timeFrame: 48 hours
Other outcomes:
measure: Knee range of motion
timeFrame: 3 months
Locations:
city: Klongluang
country: Thailand
facility: Orthopaedic department, Faculty of medicine, Thammasat university
state: Pathumthani
Study officials:
affiliation: Orthopaedics department, Thammasat University
name: Supakit Kanitnate, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05547815: Observation on the Immune Persistence of People Aged 10-60 Years Old Immunized With Five Doses of Rabies Vaccine
Official title: Single Arm, Single Center Phase IV Clinical Trial to Evaluate the Immune Persistence and Safety of Freeze-dried Human Rabies Vaccine (Vero Cell)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Rabies
Antibody
Keywords: rabies vaccine
antibody
persistence
Lead sponsor: Changchun Zhuoyi Biological Co., Ltd
Sponsor class: OTHER
First posted: 2022-09-21
Enrollment: 149
Sex: ALL
Minimum age (years): 10
Maximum age (years): 60
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: Evaluation of immune persistence after rabies vaccination in 150 people.

Detailed description: 150 subjects aged 10-60 were recruited to inoculate the frozen human rabies vaccine (Vero cells) produced and marketed by Changchun Zhuoyi Biological Co., Ltd. in the whole process of 0, 3, 7, 14 and 28 day immunization. The immunogenicity persistence and safety of the test vaccine were evaluated 14 days, 6 months and 12 months after the whole process of vaccination.

Eligibility criteria: Inclusion Criteria:

* 10-60 years old；
* Temperature on the day of admission≤37.0 ° C (axillary temperature).

Exclusion Criteria:

* Have a history of rabies vaccine immunization or use of rabies virus passive immunization agents；
* Has been diagnosed with congenital or acquired immunodeficiency disease;
* Pregnancy (including positive urine pregnancy test) or lactation, planned pregnancy preparation within 2 months.

Primary outcomes:
measure: positive conversion rate evaluation (6 months)
timeFrame: 6 months
measure: antibody titer evaluation (6 months)
timeFrame: 6 months
measure: positive conversion rate evaluation (12 months)
timeFrame: 12 months
measure: antibody titer evaluation (12 months)
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Changchun
country: China
facility: Changchun Zhuoyi Biological Co., Ltd
state: Jilin
Study officials:
affiliation: Changchun Zhuoyi Biological Co., Ltd
name: Li Miao, Dr
role: STUDY_DIRECTOR
References:
Clinical trial NCT04347915: The Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Moderate COVID-19
Official title: A Single Blind, Randomized, Placebo-controlled, Multi-center Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients Diagnosed With Moderate COVID-19
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: COVID-19
Keywords: Coronavirus disease-19(COVID-19)
Lead sponsor: Bukwang Pharmaceutical
Sponsor class: INDUSTRY
First posted: 2020-04-15
Enrollment: 64
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this clinical trial is to assess the safety and efficacy of Clevudine 120 mg versus placebo once daily administration with standard of care therapy for 14 days (maximum up to 21 days) in patients with moderate COVID-19.


Eligibility criteria: Key Inclusion Criteria:

1. Over 19 years of age
2. COVID-19 confirmed by a real-time RT-PCR tests 4 days prior to clinical trial enrollment
3. Patients with peripheral capillary oxygen saturation (SPO2) greater than 94% at the time of screening
4. Patients whose body temperature is measured according to the measured area without taking a fever reducer during screening:

   \[armpit of greater than 37.0 °C or an oral of greater than 37.2 °C; Patients with rectum greater than 37.6 °C or eardrum greater than 37.5 °C\] (Notes: Although you take a fever reducer, you can still be enrolled in after investigator's judgement whether there is fever or not.)
5. Patients with evidence of lung invasions as a result of radiation tests

Exclusion Criteria:

1. Patients who need breathing device (for example, Invasive ventilation, Invasive mechanical ventilation, Extra-corporeal membrane oxygenation).
2. Patients who participated in other clinical trials related to COVID-19.
3. Patients who were administered drugs directly to COVID-19 24 hours prior to the start of the study.
4. Patients whose AST or ALT has increased by more than 5 times the normal lab value.

Primary outcomes:
measure: The rate of subjects tested as negative SARS-Coronavirus-2 (SARS-CoV-2)
timeFrame: within 15days
Secondary outcomes:
measure: The rate of subjects tested as negative SARS-Coronavirus-2 (SARS-CoV-2) in consecutive two days of Real-Time RT-PCR tests
timeFrame: Day 4, 8, 11, 15, 22, 29(or EOT) day comparing the baseline
measure: The rate of subjects indicated by the improvement of lung invasive
timeFrame: within Day 29 (or EOT)
measure: The change of viral load
timeFrame: Day 4, 8, 11, 15, 22, and 29(or EOT) comparing the baseline
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Korea University Guro Hospital
Study officials:
affiliation: Korea University Guro Hospital
name: Woo-Joo Kim, M.D.,Ph.D.
role: PRINCIPAL_INVESTIGATOR
References: